Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

2.89 -5.86

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

3.13

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+190.43% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-44M 287M
Iepriekšējā atvēršanas cena	8.75
Iepriekšējā slēgšanas cena	2.89

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. sept. 23:56 UTC

Correlated Moves

TE Connectivity PLC declined slightly in after-market trading, amid concerns over economic momentum following a drop in the Richmond Fed Manufacturing Index.

2026. g. 22. sept. 23:56 UTC

Raymond James Financial Inc is trading modestly lower in after-market hours, continuing a decline since Tuesday and remaining near the low end of its one-month range.

2026. g. 22. sept. 23:56 UTC

Correlated Moves

Hess Midstream LP is trading lower in after-market hours, following a flat session and amid a decline in shares of Targa Resources Corp.

2026. g. 22. sept. 23:56 UTC

Correlated Moves

Agree Realty Corp is trading slightly higher in after-market hours, influenced by positive earnings reports from consumer discretionary companies.

2026. g. 22. sept. 23:56 UTC

Plumas Bancorp remains roughly flat in after-market trading, showing little change since Tuesday's close and oscillating around the midpoint of its one-month trading range.

2026. g. 22. sept. 23:56 UTC

Correlated Moves

Delek US Holdings Inc is trading lower in after-market hours, potentially in sympathy with HF Sinclair Corp, which has also declined.

2026. g. 22. sept. 23:55 UTC

Andersons Inc is experiencing notable gains in after-market trading, recovering from previous lower closes but remains below its 20-day moving average.

2026. g. 22. sept. 23:55 UTC

Pentair PLC is trading modestly higher in after-market hours, continuing a gradual increase, though it remains below its 20-day moving average.

2026. g. 22. sept. 23:55 UTC

Healthequity Inc. is trading modestly lower in after-market hours, continuing a decline from Tuesday's close and remaining below its 20-day moving average.

2026. g. 22. sept. 23:55 UTC

M&T Bank Corp is trading modestly higher in after-market hours, remaining above its opening level despite a slight pullback during the regular session.

2026. g. 22. sept. 23:55 UTC

Darling Ingredients Inc is trading modestly lower in after-market hours, continuing a four-session decline and remaining significantly below its 20-day moving average.

2026. g. 22. sept. 23:55 UTC

News

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

2026. g. 22. sept. 23:52 UTC

CarMax Inc. is trading modestly lower in after-market hours, continuing a decline since Tuesday's close and remaining below its 20-day moving average.

2026. g. 22. sept. 23:51 UTC

News

Itron Inc's stock is declining in after-market trading, despite the launch of its Riva IEC Grid Edge Portfolio in the Asia Pacific region.

2026. g. 22. sept. 23:51 UTC

MACOM Technology Solutions Holdings Inc is up in after-market trading, continuing a trend of seven consecutive higher daily closes and remaining above its 20-day moving average.

2026. g. 22. sept. 23:51 UTC

Old Dominion Freight Line Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a brief rise earlier.

2026. g. 22. sept. 23:51 UTC

First Solar Inc is trading modestly lower in after-market hours, following a notable dip earlier in the session and remaining below its 20-day moving average.

2026. g. 22. sept. 23:51 UTC

Eversource Energy is trading modestly higher in after-market hours, despite recent lower performance and positioning below its 20-day moving average.

2026. g. 22. sept. 23:51 UTC

Nucor Corp is trading modestly lower in after-market hours, continuing a downward trend since Tuesday's close and positioned below its 20-day moving average.

2026. g. 22. sept. 23:51 UTC

Targa Resources Corp is seeing a modest decline in after-market trading, continuing a trend of three consecutive lower daily closes.

2026. g. 22. sept. 23:51 UTC

Correlated Moves

SM Energy Co is trading modestly lower in after-market hours, continuing a decline amid concerns from the Richmond Fed Manufacturing Index's unexpected fall.

2026. g. 22. sept. 23:51 UTC

Brazil's Unemployment Rate Set to Release on September 29, Expected to Reflect Continued Labor Market Improvement Amid Global Economic Concerns.

2026. g. 22. sept. 23:51 UTC

Australia's S&P Global Services PMI at 51.4 signals slight expansion, but mixed retail forecasts raise concerns about consumer spending ahead of the holiday season.

2026. g. 22. sept. 23:51 UTC

Australia's S&P Global Manufacturing PMI Flash at 49.3 Signals Contraction, Raising Concerns Over Economic Growth and Potential Monetary Policy Adjustments.

2026. g. 22. sept. 23:51 UTC

Japan's Industrial Production Report Set for Release on September 29, Amidst Positive Trends and Global Economic Influences.

2026. g. 22. sept. 23:51 UTC

Japan's Retail Sales Data Release on September 29 Faces Caution Amid Interest Rate Hike and Yen Weakness.

2026. g. 22. sept. 23:50 UTC

News

Coeur Mining plans a record $158 million exploration investment for 2026, more than double 2025's budget, as shares rise in after-market trading.

2026. g. 22. sept. 23:50 UTC

Cinemark Holdings Inc is declining in after-market trading, falling from earlier gains and nearing the lower end of its one-month trading range.

2026. g. 22. sept. 23:50 UTC

Veeva Systems Inc is trading modestly higher in after-hours action, remaining below its 20-day moving average and around the midpoint of its one-month range.

2026. g. 22. sept. 23:50 UTC

Aspen Aerogels Inc is trading lower in after-market hours, showing a significant decline from Tuesday's close, though still above its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

190.43% augšup

Prognoze 12 mēnešiem

Vidējais 8.8 USD 190.43%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.